Medication cardiotoxicity: potential of prevention and correction (review)

Bibliography:
1. Ayza MA, Zewdie KA, Tesfaye BA, et al. The Role of Antioxidants in Ameliorating Cyclophosphamide-lnduced Cardiotoxicity. Oxid Med Cell Longev 2020; 10 May (2020): 4965171. DOI: 10.1155/2020/4965171.
2. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005; 104 (11): 2492-98. DOI: 10.1002/cncr. 21478.
3. Michel L, Rassaf T, Totzeck M, et al. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vase. 2019; 25: 100420. DOI:10.1016/j. ijcha. 2019.100420.
4. ESC Memorandum on cancer treatment and cardiovascular toxicity, developed under the auspices of the ESC practice Committee 2016. Reprint. Scientific ed. by D.V. Duplyakov. Russian journal of cardiology 2017; 3 (143): 105-39. URL: http://dx.doi.org/10.15829/1560-4071-2017-3-105-139 (15Aug 2020).
5. Chang НМ, Moudgil R, Scarabelli Т, et al. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017; 70 (20): 2536-51. DOI:10.1016/j. jacc. 2017.09.1096.
6. Chotenimitkhun R, D'Agostino RJr, Lawrence JA, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol 2015; 31 (3): 302-7.
7. Riad A, Bien S, Westermann D, et al. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 2009; 69 (2): 695-9.
8. Taniguchi I. Clinical significance of cyclophosphamide-induced cardiotoxicity. Internal Medicine 2005; 44 (2): 89-90. DOI: 10.2169/internalmedicine. 44.89.
9. Colombo A, Meroni CA, Cipolla CM, Cardinale D. Managing cardiotoxicity of chemotherapy. Current Treatment Options in Cardiovascular Medicine 2013; 15 (4): 410-24. DOI: 10.1007/s11936-013-0248-3.
10. Cardioxane. Govenmental Registry of drugs of Russian Federation. URL: https://clck.ru/QibNc (15 Aug 2020).
11. Fernandes RRA, Vianna CM, Freitas PG, et al. Economic assessment of dexrazoxane in prophylaxis of cardiotoxicity in children undergoing chemotherapy with anthracyclines. Cad Saude Publica 2019; 35 (9): e00191518. DOI: 10.1590/0102-311X00191518.
12. Ignatova EO, Frolova MA, Stenina MB, et al. Efficacy and toxicity of an alternating multicomponent neoadjuvant chemotherapy regimen for locally advanced breast cancer with a triple negative phenotype. Malignant tumors 2017; (4): 29-40.
13. Drug-related side effects and adverse reactions. URL: https://en.citizendium.org/wiki/Drug-related_side_effects_and_ adverse_reactions (1 Aug 2020).
14. EIGhandourAH, Sorady M, AzabS, El Rahman M. Human heart-type fatty acid-binding protein as an early diagnostic marker of doxorubicin cardiac toxicity. Hematology Reviews 2009; 1 (1): 6. DOI: 10.4081/hr. 2009. e6.
15. Iqubal A, Iqubal MK, Sharma S, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sci 2019; (218): 112-31.
16. Immune checkpoint inhibition and autoimmunity: rheumatological problems. Scientific and practical rheumatology 2018; 56 (1): 5-9.
17. Bedritsky SA, Larionova WB, Snegovoy AV. Clinical recommendations for cardiovascular toxicity induced by chemotherapy and targeted drugs. Moscow, 2014. URL: http://www.oncology.ru/association/clinical-guide-lines/2014/14.pdf (15 Aug 2020).
18. Kolyadina IV, Poddubnaya IV, Trofimova OP, et al. Evolution of local and drug treatment of stage I breast cancer: data analysis over the past 27 years. Modern technologies in medicine 2014: 6 (1): 54-61.
19. Shevchuk 00, Posokhova ЕА, Sakhno LA, Nikolaev VG. Theoretical ground for adsorptive therapy of anthracyclines cardiotoxicity. Exp Oncol 2012; 34 (4): 314-322.
20. Virani SA, Dent S, Brezden-Masley C, et al. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Canadian Journal of Cardiology 2016; 32 (7): 831-41. DOI: 10.1016/j. ejea. 2016.02.078.
21. Henninger C, Huelsenbeck S, Wenzel P, et al. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin. Pharmacol Res 2015; (91): 47-56.
22. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nature Reviews Clinical Oncology 2009; 6 (11): 638-47. DOI: 10.1038/nrclinonc. 2009.146.
23. Effect of systemic polychemotherapy on the state of the cardiovascular system in lymphoproliferative diseases. Rostov-on-Don, 2010. URL: https://clck.ru/Qibhd (12Aug 2020).
24. Buzatto IP, Ribeiro-Silva A, Andrade JM, et al. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Braz J Med Biol Res 2017; 50 (2): e5674. DOI:10.1590/1414-431X20165674.
25. Seliverstova DV, Evsina OV. Cardiotoxicity of chemotherapy. Heart: a journal for medical practitioners 2016; 15 (1): 50-7.
26. Kusumoto S, Kawano Н, Hayashi Т, et al. Cyclophosphamide-induced cardiotoxicity with a prolonged clinical course diagnosed on an endomyocardial biopsy. Internal Medicine 2013; 52 (20): 2311-2315. DOI: 10.2169/internalmedicine. 52.0347.
27. Kanda Y, Matsumura T, Maki K, et al. Fatal cardiac toxicity in two patients receiving same-day administration of cyclophosphamide and cytarabine as conditioning for hematopoieticstem cell transplantation. Haematologica 2001; 86 (9): 1002-3.
28. Michel L, Rassaf T. Cardio-oncology: need for novel structures. Eur J Med Res 2019; 24 (1). URL: https:// eurjmedres.biomedcentral.com/articles/10.1186/s40001 -018-0 359-0 (12 Aug 2020).
29. Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev2011; 6: CD003917.
30. Escudier M, Cautela J, Malissen N. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 2017; (136): 2085-7.
31. Minotti G. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs. J Pharmacol Exp Ther 2013 Sep; 346 (3): 343-9.
32. Reznikova EA, Kosenok VK, Nechaeva Gl, et al. New approaches to the treatment of locally advanced breast cancer using the drug "Reamberin" (NPF "Polisan"). Bulletin of the St. Petersburg state medical Academy named after I.I. Mechnikov 2005; 6 (2): 87-91.
33. Database of registered clinical trials ClinicalTrials. gov. URL: https://clinicaltrials. gov/ct2/results?cond=dexrazoxane (15 Aug 2020).
34. Barbar T, Mahmood SS, Liu JE. Cardiomyopathy Prevention in Cancer Patients. Cardiol Clin 2019; 37 (4): 441-7.
35. Robinson LL, Green DM, Hudson M, et al. Long-Term outcomes of adult survivors of childhood cancer. Results from the childhood cancer survivor study. Cancer Supplement 2005; (104): 2557-64.
36. WHO Collaborating Centre for International Drug Monitoring. VigiBase. URL: http://www.vigiaccess.org/(2Aug 2020).
37. Seicean S, Seicean A, Plana JC, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 2012; 60 (23): 2384-90.
38. Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002; 8 (6): 416-22.
39. Coppini R, Mazzoni L, Ferrantini C, et al. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. Circ Heart Fail 2017; 10 (3): e003565. DOI: 10.1161/CIRCHEARTFAILURE. 116.003565. URL: https://pubmed.ncbi.nlm.nih.gov/28255011/(13Aug 2020).
40. Morandi P, Ruffini PA, Benvenuto GM, et al. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005; 35 (4): 323-34.
41. Fisher PW, Salloum F, Das A, et al. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005; 111 (13): 1601-10.
42. Jin Z, Zhang J, Zhi H, et al. Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. J Cardiol 2013; 62 (2): 110-16.
43. Kivel R, Bry M, Robciuc MR, et al. VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med 2014; 6 (3): 307-21.
44. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety 2000; 22 (4): 263-302. DOI: 10.2165/00002018-200022040-00002.
45. Urigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA: A Cancer Journal for Clinicians 2016; 66 (4): 309-25. DOI: 10.3322/caac. 21341.
46. Varricchi G, Ameri P, Cadeddu C, et al. Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Front Physiol 2018; (9): 167.
47. Curigliano G, Cardinale D, SuterT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology2012;(7):vii155-vii166. DOI:10.1093/annonc/mds293.
48. Kang M, Kim Kl, Song Y, et al. Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients. J Chemother 2012; 24 (5): 292-6. DOI: 0.1179/1973947812Y 0000000038.
49. Trastuzumab. The registry of drugs. URL: https:// www.rlsnet.ru/mnn_index_id_2873. htm#pobochnye-dejstviya--veshhestva-trastuzumab/(25 Aug 2020).
50. Filatov AG, Temirbulatov IA, Yakh'yaev YaB, et al. Treatment of heart failure in the patient with oncopatology. Annals of Arytmology 2018: 15 (4): 240-4.